Literature DB >> 24104481

Chronic kidney disease in general populations and primary care: diagnostic and therapeutic considerations.

Maarten W Taal1.   

Abstract

PURPOSE OF REVIEW: The majority of people with chronic kidney disease (CKD) are managed by primary care physicians and nurses, but much of the initial research on CKD care was based in secondary care. The purpose of this article is to review the important recent studies of CKD in primary care that are starting to provide an evidence base for the strategies to improve the management and outcomes of the unreferred majority of people with CKD. RECENT
FINDINGS: People with CKD in primary care populations differ substantially from those familiar to nephrologists in secondary care by being older, having less reduction in glomerular filtration rate (GFR) and lower prevalence of proteinuria. These differences have important implications for management priorities. Detailed studies have identified widespread deficiencies in the care of patients with CKD in primary care (though these are also reported in secondary care). Interventions that may improve performance include automated reporting of estimated GFR, incentivizing primary care practitioners to achieve therapeutic goals and quality improvement strategies such as audit-based education.
SUMMARY: Studies have identified a need for improved management of CKD in primary care as well as methods to achieve this. Future studies should focus on the promotion of self-management through telemedicine and the Internet.

Entities:  

Mesh:

Year:  2013        PMID: 24104481     DOI: 10.1097/MNH.0b013e328365adf6

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  4 in total

1.  Provision of care for chronic kidney disease by non-nephrologists in a developing nation: a national survey.

Authors:  S Al Shamsi; A Al Dhanhani; M M Sheek-Hussein; O Bakoush
Journal:  BMJ Open       Date:  2016-08-01       Impact factor: 2.692

2.  Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial.

Authors:  Khai P Ng; Poorva Jain; Paramjit S Gill; Gurdip Heer; Jonathan N Townend; Nick Freemantle; Sheila Greenfield; Richard J McManus; Charles J Ferro
Journal:  BMJ Open       Date:  2016-02-25       Impact factor: 2.692

Review 3.  Developments in renal pharmacogenomics and applications in chronic kidney disease.

Authors:  Ariadna Padullés; Inés Rama; Inés Llaudó; Núria Lloberas
Journal:  Pharmgenomics Pers Med       Date:  2014-08-28

Review 4.  Chronic kidney disease: identification and management in primary care.

Authors:  Simon Ds Fraser; Tom Blakeman
Journal:  Pragmat Obs Res       Date:  2016-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.